Biopeople

Finance and pharma experts

Finance and pharma experts

25.07.2014 - With the appointment of Ann-Tove Kongsnes and Hilde Furberg to its board of directors, Swedish specialty pharma company Pharmalink AB has gained experts from both business development and pharmaceuticals.

Ann-Tove Kongsnes is an Investment Director at Pharmalink investor company Investinor, which is Norway’s largest investor in venture and expansion capital. She was previously an investment manager at ProVenture Managment AS and worked as a Business Development Manager at Leiv Eiriksson Nyskaping AS, among others. In addition to Pharmalink, Kongsnes is a board member of Investinor’s portfolio companies Ayanda AS, Nordic Seafarms AS, Polight AS, and Soundrop AS. She is also deputy board member at Bergenbio AS and head of International Affairs at Investinor.

Hilde Furberg has 30 years of experience in the pharmaceutical industry. She is currently Senior Vice President Rare Disease EMEA at Sanofi’s Genzyme, which she joined in 2002. Prior to Genzyme, Furberg spent 15 years at health care company Baxter in various business roles of increasing seniority, before which she was involved in the start-up of Pharmalink. She used to sit on the board of companies such as Algeta ASA, Clavis Pharma ASA, Pronova Biopharma ASA and Probi AB.

At the shareholders’ meeting that saw the two new board members, Elisabeth Lindner stepped down from the board while Olav Hellebø was also elected new member.

25.02.2014 The European biotechnology industry association EuropaBio has named Beat Spaeth as its new Director of Agricultural Biotechnology.

He is assuming the post in mid-February. The German and Swiss national has been working for the association as its Public Affairs Manager and Senior Manager in the agri-biotech team since 2011, and has many years of experience in European public affairs. Spaeth is taking over from Carel du Marchie Sarvaas, who has led EuropeBio’s agricultural biotech team for the past four years.

21.02.2014 British drug developer Heptares Therapeutics named Dr. Tim Tasker Chief Medical Officer and VP of Development in January.

The physician, who brings in 30 years of clinical experience from senior positions at GlaxoSmithKline and Evotec, will lead the company's programmes of novel GPCR-targeted agents in multiple therapeutic areas. He takes over from Dr. David McGibney, who is returning to his role as a senior clinical advisor.

20.02.2014 Swiss allergy vaccine developer Anergis SA has brought in some outside expertise by appointing Dr. Dino Dina to its Board of Directors.

Anergis

Dina brings Anergis extensive experience in R&D of vaccines for allergy, cancer and infectious diseases, as well as in building successful US biopharma companies. He served as the CEO of vaccine specialist Dynavax Technologies Corporation, and previously worked in positions with increasing responsibility at Chiron Corp.

11.02.2014 Amgen has named Michael Kelly as interim chief financial officer after Jonathan Peacock resigned the position in January. Kelly will be responsible for the finance and investor relations operations of the biotech company.

Amgen

Kelly joined Amgen in 2003 and has been in the same position in May 2010. Back then, he was named acting CFO after Robert Bradway was promoted to president and chief operating officer. Kelly most recently served as CFO for international commercial operations. Since 2005, he also served for five years as chief accounting officer.

11.02.2014 Dr. Constance Hoefer has been named the chief development officer of pharmaceutical company Priaxon where she will be responsible for non-clinical and early clinical development projects.

Merck

Before joining the Munich-based firm, Hoefer was vice-president and head of non-clinical development at Medigene. She has more than 20 years of international non-clinical development and management experience in academic and regulatory as well as industry roles in pharmaceutical and biotech companies. 

10.02.2014 Merck Serono has appointed Dr. Steven Hildemann as Global Chief Medical Officer (CMO) and Head of Global Medical and Safety.

Merck

Hildemann will be responsible for Global Medical Affairs, Global Drug Safety and External Scientific Affairs for Merck Serono, biopharmaceutical division of Merck. He will also become a member of the R&D Executive Leadership Team. In addition, Hildemann will be responsible for medical governance, chairing the Medical Safety and Ethics Board and the Bioethics Committee.

Prior to joining Merck Serono, Hildemann was Associate Vice President, Global Clinical Trial Operations Europe, MSD. Hildemann succeeds Dr. Florian Bieber who left the company in December 2013 to pursue other opportunities.

04.02.2014 Dr. Ursula Redeker has joined the executive board of Roche Diagnostic GmbH. She also replaces Thomas Schmid as spokesperson of Roche Deutschland Holding GmbH, the German branch of Swiss biotech giant Roche.

Roche

Redeker, who gained her doctorate in organic chemistry, has worked for Roche since 1994. Her last position was that of head of Technical Development Biologics Europe, Technical Operations. Before that, she was lead on the technical development of therapeutical proteins in Europe and contributed to the development of several prominent products, such as therapies for breast cancer and leukaemia.

03.02.2014 Epistem has appointed Dr. Allan Brown as Chief Operation Officer of their Diagnostics division. With the appointment, Manchester-based Epistem reacts to the increasing influence of diagnostics and personalised medicine in their portfolio.

Epistem

Before Dr. Brown joined Epistem, he worked for Qiagen Ltd. and managed the final development and launch of the company’s first FDA-approved products. Prior to that, he spent 17 years  at Tepnel Life Sciences, latterly as Divisional Managing Director.

31.01.2014 Thomas Broeer, managing director of Kent Pharmaceuticals, has taken over the role of chair at the British Generic Manufacturers Association (BGMA). The association has appointed him for the next two years.

Thomas Broeer

He replaces Kim Innes, who will continue to act as vice-chair for another year. Broeer has worked in the pharmaceutical business for more than 20 years – both within the generic and branded industries. Before his switch to Kent in 2013, he held senior management roles with Mylan in the UK and in Germany.

28.01.2014 In mid-January, Horizon Discovery – UK's provider of research tools to support the development of personalised medicines – appointed Dr. Ian Gilham Chairman of its Board of Directors.

Horizon Discovery

His health care industry career spans thirty years of experience. The current Chairman of genetic testing company Muliplicom and POC diagnostics provider Biosurfit comes in from in vitro diagnostics developer Axis-Shield plc which was taken over by Alere in 2011. Prior Gilham held senior positions with healthcare companies such as GlaxoSmithKline, Abbott Laboratories, Celltech and Amersham.

Vorherige Seite4/19Nächste Seite

Events

All Events

Stock list

All quotes

TOP

  • NOVACYT (F)4.98 EUR5.96%
  • STALLERGENES (F)53.50 EUR4.37%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • THROMBOGENICS (B)9.54 EUR-5.07%

TOP

  • WILEX (D)3.15 EUR314.5%
  • SANTHERA (CH)68.55 CHF90.4%
  • ADDEX (CH)4.08 CHF82.1%

FLOP

  • MERCK KGAA (D)65.43 EUR-48.6%
  • HYBRIGENICS (F)1.77 EUR-29.2%
  • PROSENSA (NL)9.81 USD-22.6%

TOP

  • SANTHERA (CH)68.55 CHF3489.0%
  • GW PHARMACEUTICALS (UK)427.00 GBP729.1%
  • PAION (D)2.79 EUR316.4%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • THROMBOGENICS (B)9.54 EUR-69.5%

No liability assumed, Date: 25.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products